Print Page | Sign In
Michael Wein, MD
Share |

Michael Wein, MD, is Chief of Allergy at Indian River Medical Center and serves on the faculty at Florida State University College of Medicine. He completed his undergraduate work at Brown University, an internal medicine residency at Vanderbilt University, and his post-doctoral fellowship at Johns Hopkins Hospital in the division of Allergy & Immunology. He is board-certified by the American Board of Allergy and Immunology and also by the American Board of Internal Medicine. 

Dr. Wein is Past President of the Florida Allergy, Asthma, and Immunology Society and is a Fellow of the American Academy of Allergy, Asthma and Immunology. He has authored several publication including the chapter on allergic rhinitis in Conn’s Current Therapy, 2006 edition, and has served editorial roles for DynaMed Online and Prescribers Letter and is currently an Advisory Board Member of Boston-based Wellness Workdays. He co-authored a study on Epi-pen which was published in Annals of Allergy in 2015 and subsequent featured on CNN. His previous publications relate mostly to allergic inflammation, eosinophils, and adhesion molecules. 

His offices are located in Vero Beach and Port Saint Lucie and he enjoys learning about dermatology from his friends practicing dermatology in his community.

 

Biologics in Dermatology

Objectives:

  1. Practical aspects of IVIG therapy
  2. Therapeutic pipeline for atopic dermatitis
  3. Differentiating among biologics for psoriasis

Needs: 

  1. New advances in dermatologic treatment
  2. Availability of new medication(s) or indication(s)
  3. Advances in medical knowledge

References: 

  1. Maurer MD, M. et al. “Ligelizumab for Chronic Spontaneous Urticaria.” N Engl J Med. 2019; 381: 1321-1332.
  2. Saunte DM, Mrowietz U, Puig L, Zachariae C. “Candid infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management.” BJD. 2017 July; 177(1): 47-62.
  3. Simpson EL, et al. “Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.” N Engl J Med. 2016; 377: 235-2348.

Core Competencies: 2, 3

2902 North Baltimore Street | P.O. Box 7525 | Kirksville, Missouri 63501

660-665-2184 | 1-800-449-2623 | 660-627-2623

General Terms of Use Policy
The AOCD web site and AOCD apps contain copyrighted material and other proprietary information, which may include, but is not limited to: text, software, photos, video, graphics and audio. It is not permitted to modify, publish, transmit, participate in the transfer or sale, create derivative works, or in any way exploit any of the content, in whole or in part.

The AOCD limits permission for downloading education material for personal use only.